2022-03-10 09:11:40 GOVX GeoVax Labs
03/10/22 03/1009:11 03/10/2209:11 | GeoVax Labs announces publication on COVID-19 investigational vaccineA COVID-19 investigational vaccine, developed by City of Hope scientists and now licensed to GeoVax Labs produced a robust neutralizing antibody and T cell response against SARS-CoV-2 with no significant side effects in a Phase 1 clinical trial led by John Zaia, M.D., Aaron D. Miller and Edith Miller Chair for Gene Therapy, according to a study published today in The Lancet Microbe. COH04S1 is uniquely different than the many vaccines that have been developed because it targets both the spike and nucleocapsid proteins, in contrast to the current U.S. Food and Drug Administration-approved COVID-19 vaccines, which only target the spike protein. COH04S1 is being studied in a first-of-its-kind Phase 2 clinical trial for immunocompromised cancer patients who have difficulty producing antibodies and largely depend on T cells to protect against the virus responsible for COVID-19. Likewise, COH04S1 is also being evaluated in a Phase 2 vaccine booster trial format, which is aimed at evaluating how COH04S1 can boost pre-existing vaccine immunity to spike while also causing a strong immune response to nucleocapsid. COH04S1 elicited neutralizing antibodies against the virus' spike protein, which interacts with the human cellular ACE2 receptor, allowing the virus to enter cells of the lung, heart and other organs, resulting in damage and significant inflammation. These neutralizing antibodies were effective against the original SARS-CoV-2 and subsequent viral variants. T cells were produced against the SARS-CoV-2 nucleocapsid protein, as well as its spike protein, after just one dose of COH04S1. In November 2021, GeoVax licensed the vaccine for further development and commercialization, including potentially as a first-line COVID-19 vaccine. GeoVax has now designated the vaccine as GEO-CM04S1. For the Phase 1 trial at City of Hope, 58 healthy adult volunteers participated and 34 participants received two doses of COH04S1 28 days apart. Five received two placebo doses and 13 volunteers received a first dose of the vaccine and a second dose of the placebo. Volunteers who received the placebo were informed 56 days after first injection - of either the vaccine or placebo - that they didn't receive one or both vaccine injections. They were offered COH04S1 or one of the then-emergency use authorized vaccines as a second dose. T cells against the spike and nucleocapsid proteins were induced following the first dose of COH04S1. Following the second dose, given four weeks after the first, high amounts of neutralizing antibodies were detected at the next monitoring period. All vaccinated volunteers reached the primary immunological endpoint, defined as a four-fold increase of antibodies against the spike or nucleocapsid protein eight weeks after the first dose. The Phase 2 clinical trial of COH04S1 is the first to study the safety and effectiveness of an investigational vaccine in patients with blood cancer who have received a bone marrow transplant or chimeric antigen receptor T therapy. The trial is also the first to compare an investigational COVID-19 vaccine to the Pfizer Cominarty vaccine in people who are immunocompromised and receiving immunosuppressive therapy. The Phase 2 booster study is for healthy individuals, 18 years of age and older, who were previously vaccinated with one of the FDA-approved mRNA vaccines or the FDA-authorized Johnson & Johnson vaccine. The study is designed as a dose-escalation trial to evaluate the safety profile and immune response of COH04S1 as a booster shot. The immunological responses measured will include both the level of neutralizing antibodies against SARS-CoV-2, including omicron and T cell responses. |
---|
Hot Stocks
|
Micron exec sells $3.16M in common stock »
20:29 01/31/23 01/3120:29 01/31/2320:29
MU
Micron
In a regulatory filing,… Story temporarily locked. ShowHide Related Items >><<
|
Earnings
|
Notable companies reporting before tomorrow's open »
20:25 01/31/23 01/3120:25 01/31/2320:25
TMO
Thermo Fisher
T-Mobile
Altria Group
Boston Scientific
Humana
AmerisourceBergen
Fortive
Dynatrace
Peloton
Brinker
Notable companies… Notable companies reporting before tomorrow's open, with earnings consensus, include Thermo Fisher (TMO), consensus $5.19... T-Mobile (TMUS), consensus $1.10... Altria (MO), consensus $1.17... Boston Scientific (BSX), consensus 47c... Humana (HUM), consensus $1.46... AmerisourceBergen (ABC), consensus $2.63... Fortive (FTV), consensus 84c... Dynatrace (DT), consensus 21c... Peloton (PTON), consensus (64c)... Brinker (EAT), consensus 52c. ShowHide Related Items >><<
|
Recommendations
|
Oshkosh price target raised to $100 from $93 at Baird »
20:14 01/31/23 01/3120:14 01/31/2320:14
OSK
Oshkosh
Baird analyst Mircea… Story temporarily locked. ShowHide Related Items >><<
|
Hot Stocks
|
Cathie Wood's ARK Investment bought 1.1M shares of Invitae today
20:07 01/31/23 01/3120:07 01/31/2320:07
NVTA
Invitae
ShowHide Related Items >><<
|
Hot Stocks
|
Cathie Wood's ARK Investment bought 20.7K shares of Velo3D today
20:07 01/31/23 01/3120:07 01/31/2320:07
VLD
Velo3D
ShowHide Related Items >><<
|
Earnings
|
Waste Management sees FY23 revenue growth of 4.0% to 5.5% »
19:17 01/31/23 01/3119:17 01/31/2319:17
WM
Waste Management
The projected growth rate… Story temporarily locked. ShowHide Related Items >><<
|
Earnings
|
Waste Management reports Q4 EPS $1.30 , consensus $1.41 »
19:13 01/31/23 01/3119:13 01/31/2319:13
WM
Waste Management
Reports Q4 revenue… Story temporarily locked. ShowHide Related Items >><<
|
Downgrade
|
Vorwerk Group SE downgraded to Hold from Buy at Jefferies »
19:11 01/31/23 01/3119:11 01/31/2319:11
FRVWY
Vorwerk Group SE
Jefferies analyst Martin… Story temporarily locked. |
Recommendations
|
Sysco well positioned to drive accelerating growth, says Stephens »
19:02 01/31/23 01/3119:02 01/31/2319:02
SYY
Sysco
Stephens analyst Joshua… Story temporarily locked. ShowHide Related Items >><<
|
Hot Stocks
|
Marin Software announces new integration with Yahoo »
18:58 01/31/23 01/3118:58 01/31/2318:58
MRIN
Marin Software
Marin Software announced… Story temporarily locked. |
Hot Stocks
|
Pfizer CEO: Our best days are still ahead of us »
18:49 01/31/23 01/3118:49 01/31/2318:49
PFE
Pfizer
In an interview on… Story temporarily locked. ShowHide Related Items >><<
|
Recommendations
|
Dover price target raised to $165 from $144 at Baird »
18:42 01/31/23 01/3118:42 01/31/2318:42
DOV
Dover
Baird analyst Mircea… Story temporarily locked. ShowHide Related Items >><<
|
Upgrade
|
Linamar upgraded to Outperform from Market Perform at BMO Capital »
18:37 01/31/23 01/3118:37 01/31/2318:37
LIMAF
Linamar
BMO Capital analyst Peter… Story temporarily locked. ShowHide Related Items >><<
|
Upgrade
|
Magna upgraded to Outperform from Market Perform at BMO Capital »
18:37 01/31/23 01/3118:37 01/31/2318:37
MGA
Magna
BMO Capital analyst Peter… Story temporarily locked. ShowHide Related Items >><<
|
Upgrade
|
Martinrea upgraded to Outperform from Market Perform at BMO Capital »
18:36 01/31/23 01/3118:36 01/31/2318:36
MRETF
Martinrea
BMO Capital analyst Peter… Story temporarily locked. ShowHide Related Items >><<
|
Upgrade
|
Canadian Tire upgraded to Outperform from Market Perform at BMO Capital »
18:35 01/31/23 01/3118:35 01/31/2318:35
CDNAF
Canadian Tire
BMO Capital analyst Peter… Story temporarily locked. ShowHide Related Items >><<
|
Downgrade
|
Metro downgraded to Market Perform from Outperform at BMO Capital »
18:34 01/31/23 01/3118:34 01/31/2318:34
MTRAF
Metro
BMO Capital analyst Peter… Story temporarily locked. ShowHide Related Items >><<
|
On The Fly
|
Fly Intel: After-Hours Movers »
18:32 01/31/23 01/3118:32 01/31/2318:32
CACC
Credit Acceptance
O-I Glass
Stryker
Edwards Lifesciences
AMD
Mondelez
Jasper Therapeutics
Snap
Hawaiian Holdings
Electronic Arts
Match Group
Western Digital
Varex Imaging
Juniper
Super Micro Computer
Ashland
Houlihan Lokey
Taysha Gene Therapies
Poseida Therapeutics
Check out this evening's… ShowHide Related Items >><<
|
Hot Stocks
|
Mesoblast resubmits BLA to FDA for remestemcel-L »
18:31 01/31/23 01/3118:31 01/31/2318:31
MESO
Mesoblast
Mesoblast Limited… Story temporarily locked. ShowHide Related Items >><<
|
Earnings
|
Boston Properties cuts FY23 FFO view to $7.08-$7.18 from $7.15-$7.30
18:28 01/31/23 01/3118:28 01/31/2318:28
BXP
Boston Properties
Consensus $7.18. ShowHide Related Items >><<
|
Hot Stocks
|
Poseida Therapeutics founder and executive chairman Eric Ostertag to retire »
18:28 01/31/23 01/3118:28 01/31/2318:28
PSTX
Poseida Therapeutics
Earlier this evening,… Story temporarily locked. ShowHide Related Items >><<
|
Earnings
|
Boston Properties sees Q1 FFO $1.66-$1.68
18:27 01/31/23 01/3118:27 01/31/2318:27
BXP
Boston Properties
ShowHide Related Items >><<
|
Earnings
|
Boston Properties reports Q4 FFO $1.86, consensus $1.84 »
18:27 01/31/23 01/3118:27 01/31/2318:27
BXP
Boston Properties
Reports Q4 revenue… Story temporarily locked. ShowHide Related Items >><<
|
Initiation
|
Beam Therapeutics initiated with an Overweight at Cantor Fitzgerald »
18:26 01/31/23 01/3118:26 01/31/2318:26
BEAM
Beam Therapeutics
Cantor Fitzgerald analyst… Story temporarily locked. ShowHide Related Items >><<
|
Hot Stocks
|
General Motors CEO: Couldn't be more excited about EV launches this year »
18:25 01/31/23 01/3118:25 01/31/2318:25
GM
General Motors
In an interview on… Story temporarily locked. ShowHide Related Items >><<
|